검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | CART22-65s (Autologous, humanized anti-CD22 CAR T cell therapy, Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s)) Stephan Grupp MD PhD·CD22 6 trials |
|---|---|
Overview Program | Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s) |
Overview Company | Stephan Grupp MD PhD |
Overview Modality | CGT |
Overview Target | CD22 |
Overview Indication | B-cell Acute Lymphoblastic Leukemia; B Lineage Lymphoblastic Lymphoma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | targeted chimeric antigen receptor |
PK/PD Species | All CRS (n=17, 89%) and neurotoxicity (n=4 |
PK/PD Animal (cat.) | Unknown |
PK/PD Experiment | All CRS (n=17, 89%) and neurotoxicity (n=4, 21%) events after initial infusion were grades 1-2. |
Toxicology Species | All CRS (n=17, 89%) and neurotoxicity (n=4 |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | CD22-targeted chimeric antigen receptor-modified T cells for children and adults with relapse of B-cell acute lymphoblastic leukemia after CD19-directed immunotherapy.. Relapse of B-cell acute lymphoblastic leukemia (B-ALL) with CD19-antigen loss after CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has a dismal prognosis. Novel immunotherapeutic strategies for this patient population… |
Toxicology CRS | 89% |
Clinical Data Tier / Score | A · 15 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | CART22-65s (Autologous, humanized anti-CD22 CAR T cell therapy, Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s)) Stephan Grupp MD PhD·CD22 6 trials |
|---|---|
Overview Program | Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s) |
Overview Company | Stephan Grupp MD PhD |
Overview Modality | CGT |
Overview Target | CD22 |
Overview Indication | B-cell Acute Lymphoblastic Leukemia; B Lineage Lymphoblastic Lymphoma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | targeted chimeric antigen receptor |
PK/PD Species | All CRS (n=17, 89%) and neurotoxicity (n=4 |
PK/PD Animal (cat.) | Unknown |
PK/PD Experiment | All CRS (n=17, 89%) and neurotoxicity (n=4, 21%) events after initial infusion were grades 1-2. |
Toxicology Species | All CRS (n=17, 89%) and neurotoxicity (n=4 |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | CD22-targeted chimeric antigen receptor-modified T cells for children and adults with relapse of B-cell acute lymphoblastic leukemia after CD19-directed immunotherapy.. Relapse of B-cell acute lymphoblastic leukemia (B-ALL) with CD19-antigen loss after CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has a dismal prognosis. Novel immunotherapeutic strategies for this patient population… |
Toxicology CRS | 89% |
Clinical Data Tier / Score | A · 15 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교